Appendix F: Fiscal Year 2018 Scientific Presentations

American Psychological Association | San Francisco, CA, August 2018

1. Allen, M., Kimerling, R., & Gaska, K. Patterns of adversity predict social determinants of health among veteran women.

2. Beristianos, M., Mallard, K. N., Song, J., Lane, J., Landy, M., Shields, N., Monson, C., & Wilsey Stirman, S. An examination of Cognitive Processing Therapy consultation activities on fidelity and symptom change. In M. Beristianos (Chair), Effectiveness and implementation of evidence-based psychotherapies for trauma and PTSD.


8. Kimerling, R., Allen, M., & Gaska, K. Beyond revictimization: Constellations of adversities predict for post-year IPV.


12. Rosen, C. S., Clothier, B., Noorbaloochi, S., Smith, B. N., Orazem, R., & Sayer, N. Organizational factors associated with wider reach of evidence-based psychotherapies for PTSD. In M. Beristianos (Chair), Effectiveness and implementation of evidence-based psychotherapies for trauma and PTSD.


15. Shiperd, J. C. Understanding risk and resilience for suicidal ideation and attempts in transgender veterans. In K. Lehavot (Chair), Understanding risk and resilience for suicidal ideation and attempts in transgender veterans.


Anxiety and Depression Association of America | Washington, DC, April 2018

19. Abdallah, C. Ketamine as a tool: The path to a biologically defined psychiatric disorder.


23. Gauthier, G. M., Mosher, S. J., Zax, A., Bovin, M. J., Keane, T. M., & Marx, B. P. Evaluating the association between cigarette smoking and suicide in veterans with PTSD.
Appendix F: Fiscal Year 2018 Scientific Presentations

(Angst and Depression Association of America, continued)


25. Lee, D. J., Lee, L. O., Bovin, M. J., Green, J. D., Klein, A., Rosen, R. C., Keane, T. M., & Marx, B. P. Examination of the nature and longitudinal course of PTSD and depression symptoms among OEF/OIF veterans: Preliminary results from the Veterans After-Discharge Longitudinal Registry (Project VALOR). In B. P. Marx (Chair), Understanding the nature and course of posttraumatic stress disorder symptoms: Implications of assessment and measurement strategies.


Association for Behavioral and Cognitive Therapies | San Diego, CA, November 2017


35. Creech, S. K., Benzer, J., Ebalu, T., Murphy, C. M., & Taft, C. T. National implementation of a trauma-informed intervention to prevent and end intimate partner violence in the Department of Veterans Affairs: First year outcomes. In L. McGinn (Chair), Novel targets and change mechanisms in prevention.


37. Curry, I., Lyons, R., & Norman, S. B. The impact of negative cognitions related to trauma on impairment of functioning due to pain.


40. Galovski, T. E. Treating dysregulated anger in traumatized populations: Outreach along the continuum of care. In M. A. Mackintosh (Chair), Treating dysregulated anger in traumatized populations: Outreach along the continuum of care.
Appendix F: Fiscal Year 2018 Scientific Presentations

(Association for Behavioral and Cognitive Therapies, continued)


Association for Psychological Science | San Francisco, CA, May 2018


Combat PTSD Conference | San Antonio, TX, October 2017

68. Santiago, R., Meffert, B., Hausman, C., Sawicki, D. A., & Heinz, A. J. Anger, aggression, and impulsivity: A multimodal investigation among military veterans with alcohol use disorder and PTSD.

69. Sawicki, D. A., Meffert, B., Hausman, C., Santiago, R., & Heinz, A. J. Distress tolerance, emotional awareness, hopefulness, and suicidality: An examination among military veterans with alcohol use disorder and PTSD.

70. Wiltsey Stirman, S. Personalizing treatment: Implications for clinical practice and implementation. In S. Dorsey (Chair), Personalizing behavioral therapies for anxiety- and trauma-related disorders: Using baseline characteristics to prescribe treatments and personalize treatment content.

71. Gutner, C. A. The Unified Protocol for PTSD. In J. Wachen (Chair), New frontiers in PTSD treatment.


73. Krystal, J. H. Why ketamine, why now: And where do we go from here?

74. McLean, C. P. New frontiers in PTSD treatment research. In J. Wachen (Chair), New frontiers in PTSD treatment research.
Appendix F: Fiscal Year 2018 Scientific Presentations

(Combat PTSD Conference, continued)


76. Rosen, C. S., & Sayer, N. A. Organizational factors that promote clinics’ use of evidence-based treatments for PTSD.

77. Weinstein, E., Smidt, K., Litwack, S., Unger, W., & Niles, B. L. What is Present Centered Therapy (PCT)? A closer look at the common control group in posttraumatic stress disorder clinical trials.

International Society for Traumatic Stress Studies  |  Chicago, IL, November 2017

78. Abdallah, C. PTSD and depression symptom severities are differentially associated with hippocampal subfield volume loss in combat veterans.


80. Arditte Hall, K., Rosebrock, L. E., Pineses, S. L., Rando, A., & Liverant, G. I. State and trait emotion regulation in veterans with PTSD and depression. In K. Arditte Hall (Chair), Elucidating the mechanisms of dysfunction in PTSD and depression.

81. Arenson, M., McCaslin, S. E., Neylan, T. C., & Cohen, B. Predictors of high-functioning in veterans with PTSD: Results from the Mind Your Heart Study.


83. Averill, L., Abdallah, C., Southwick, S. M., Krystal, J. H., Gelernter, J., & Pietrzak, R. H. Examining the effects of APOE genotype and PTSD on cognitive dysfunction in older veterans: Results from the National Health and Resilience in Veterans Study.

84. Bernardy, N. C., & Sherrieb, K. Innovative strategies to improve access to evidence-based PTSD treatment for rural veterans. In N. C. Bernardy (Chair), Complicated prescribing practices in VA patients with PTSD: Approaches to observation and improvement.


86. Carlson, E. B., Palmieri, P. A., & Dekel, R. What do mental health risks in primary care veterans tell us about mental health needs?


88. Cohen, Z. D., Wiltsey Stirman, S., DeRubeis, R., Smith, B. N., & Resick, P. A. Improving outcomes through a new variable selection approach for treatment selection in sexual trauma PTSD. In Z. Cohen (Chair), Precision medicine in trauma: Selecting the optimal treatment for an individual with PTSD.

89. Creech, S. K., Benzer, J., Ebalu, T., Murphy, C. M., & Taft, C. T. National implementation of a trauma-informed intervention for intimate partner violence in the Department of Veterans Affairs: First year outcomes. In S. Creech (Chair), New directions in assessing and treating intimate partner violence among women and men veterans in the Department of Veterans Affairs.


92. Galovski, T. E., & Chappuis, C. Creative fidelity: Persevering in the administration of manualized protocols despite seemingly insurmountable odds. In M. Beristianos (Chair), EBP implementation in complex treatment systems and settings: Training, access, processes, and outcomes.


95. Greenbaum, M. A., Neylan, T. C., & Rosen, C. S. Prescribing practices for PTSD-related insomnia in two cohorts of U.S. veterans. In N. C. Bernardy (Chair), Complicated prescribing practices in VA patients with PTSD: Approaches to observation and improvement.


97. Grillo, A., Iverson, K. M., & Dichter, M. E. Screening female patients for intimate partner violence in VHA: Evidence to inform modifications or de-implementation of secondary screening recommendations.


101. Iverson, K. M. Network analysis of PTSD symptoms in a sample of female veterans with and without a history of intimate partner violence. In M. Suvak (Chair), Network analysis of PTSD symptoms in a sample of female veterans with and without a history of intimate partner violence.
Appendix F: Fiscal Year 2018 Scientific Presentations

(International Society for Traumatic Stress Studies, continued)


103. Keefe, J. J., Wittey Stirman, S., Cohen, Z. D., DeRubeis, R., Smith, B. N., & Resick, P. A. What works for whom in sexual trauma PTSD: Patient characteristics indicate which treatment they are most likely to complete. In Z. Cohen (Chair), Precision medicine in trauma: Selecting the optimal treatment for an individual with PTSD.


106. Knight, J. A., Belingeri, A., & Fox, A. Variability in unique PTSD symptom patterns compared across clinical and non-clinical samples: The myriad manifestations of PTSD.


114. Maieritsch, K. P., Romero, E., Voss Horrell, S., Hessinger, J., & Hamblen, J. L. Preparatory treatment activities, are they necessary?


123. Niles, B. L., Smidt, K., Weinstein, E., & Fisher, L. M. Evidence-based psychotherapies for PTSD: How are they carried out in a real-world VA setting?


127. Rosen, C. S., Clothier, B., Noorbaloochi, S., Smith, B. N., Orazem, R., & Sayer, N. Which veterans receive evidence-based psychotherapy for PTSD. In M. Beristianos (Chair), EBP implementation in complex treatment systems and settings: Training, access, processes, and outcomes.

128. Sanders, W., Smith, B. N., & Vogt, D. Mental health and quality of life predictors of VA family service use.

129. Schnurr, P. P. Discussant. In A. Wagner (Chair), Pharmacologic agents as treatment and adjunct to psychotherapy for PTSD: Data with MDMA, oxytocin and ketamine.

130. Schnurr, P. P. Discussant. In Z. Cohen (Chair), Precision medicine in trauma: Selecting the optimal treatment for an individual with PTSD.

131. Schnurr, P. P., & Lunney, C. A. Residual symptoms following Prolonged Exposure and Present-Centered Therapy for PTSD in female veterans and soldiers. In S. Larsen (Chair), The aftermath of PTSD treatment: Characteristics associated with either residual symptoms or long-term improvement.
Appendix F: Fiscal Year 2018 Scientific Presentations

(International Society for Traumatic Stress Studies, continued)

132. Shiner, B. Anticonvulsant medication use in veterans with posttraumatic stress disorder.

133. Shiner, B. Trends in opioid use disorder diagnoses and medication treatment among veterans with posttraumatic stress disorder. In N. C. Bernardy (Chair), Complicated prescribing practices in VA patients with PTSD: Approaches to observation and improvement.


136. Spoont, M., Sayer, N., Rosen, C. S., Nelson, D., Murdoch, M., & Kehle-Forbes, S. Six months after a PTSD diagnosis – Are veterans any better?

Society of Biological Psychiatry | New York, NY, May 2018


145. Duman, R. Stress, depression and antidepressants: Remodeling synaptic connections.


Other


Appendix F: Fiscal Year 2018 Scientific Presentations

(Other, continued)


Appendix F: Fiscal Year 2018 Scientific Presentations

(Other, continued)


Appendix F: Fiscal Year 2018 Scientific Presentations

(Other, continued)


209. Pless Kaiser, A. (2018, April). Trauma and aging: Assessment and treatment among older adults and veterans. University of Massachusetts Boston Gerontology Department Faculty and Student Speaker Series, University of Massachusetts-Boston, Boston, MA.


217. Schnorr, G. (2017, October). Intravenous and intranasal rapid-acting antidepressants. 16th Annual Psychopharmacology Update, Cincinnati, OH.


